PARP 抑制剂:临床中的合成致死性
Christopher J Lord1, Alan Ashworth2
1The Cancer Research UK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. chris.lord@icr.ac.uk alan.ashworth@ucsf.edu.
概括
在BRCA突变的癌症中利用合成杀伤性. 研究探讨克服PARPi耐药性和优化综合疗法用于更广泛的癌症治疗.
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- PARP 抑制剂 (PARPi) 是一种新的癌症治疗类别.
- 它们利用合成致命性概念,针对具有特定DNA修复缺陷的瘤,特别是在BRCA1/BRCA2突变中.
- 除了具有BRCA突变的癌症外,PARPi在癌症中表现出有效性,前提是它们具有类似的DNA修复缺陷.
研究的目的:
- 审查目前对PARP抑制剂的理解.
- 探索提高其临床有效性的策略.
- 讨论PARPi治疗的挑战,包括耐药性和最佳组合方法.
主要方法:
- 对PARP抑制剂的临床前和临床研究的审查.
- 在癌症遗传学中分析合成致死性原则.
- 讨论药物耐药性机制和组合治疗策略.
主要成果:
- 由于合成致死性,PARPi在BRCA突变癌症中有效.
- 在其他具有同类重组DNA修复缺陷的癌症中,PARPi具有前景.
- 在晚期疾病中,对PARPi的耐药性是一个重大挑战.
结论:
- PARPi的开发为其他向癌症疗法提供了宝贵的见解.
- 需要进一步的研究来克服耐药性和优化组合治疗.
- 为了最大限度地提高PARPi的临床有效性,需要全面了解其机制和耐药性途径.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Restarting Stalled Replication Forks
6.5K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.5K


